NCT03337308 - A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy | Biotech Hunter

Enrollment

382

Participants

Timeline

Start Date

October 23, 2017

Primary Completion Date

June 18, 2018

Study Completion Date

July 18, 2018

Conditions

Hyperlipidemias

Interventions

COMBINATION_PRODUCT

Bempedoic Acid + Ezetimibe Fixed-Dose Combination

bempedoic acid + ezetimibe FDC 180 mg/10 mg tablet

DRUG

Bempedoic Acid

bempedoic acid 180 mg tablet

DRUG

Ezetimibe

ezetimibe 10 mg overencapsulated tablet

DRUG

Placebos

placebo tablet or capsule to match bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or bempedoic acid 180 mg tablet, or ezetimibe 10 mg capsule

Trial Locations (5)

28401

PMG Research of Wilmington, Wilmington

28625

PMG Research of Piedmont Healthcare, Statesville

37912

PMG Research of Knoxville, Knoxville

50010

PMG Research of McFarland, Ames

03060

Foundation Cardiology, Nashua